摘要
目的探讨甲状腺乳头状癌患者中BRAFV600E的突变情况及其临床意义。方法应用直接测序方法对50例甲状腺乳头状癌和20例正常甲状腺组织中的BRAFV600E进行分析。结果甲状腺乳头状癌组织中BRAFV600E突变明显高于正常甲状腺组织(46%vs 0),两者比较差异有统计学意义(P<0.001)。BRAFV600E突变与淋巴结转移和TNM分期有关(P<0.05)。结论 BRAFV600E异常是甲状腺乳头状癌发生的机制之一,与甲状腺乳头状癌的发生及发展有关。BRAFV600E可能是甲状腺乳头状癌预后的1项重要预测指标。
Objective To investigate the mutation of BRAFV600E in papillary thyroid cancer and its clinical significance.Methods Direct DNA sequencing was performed to detect BRAFV600E in 50 cases of papillary throid cancer and 20 cases of normal controls.Results The mutation of BRAF in papillary thyroid cancer were significantly higher than that in normal tissue（46% vs 0）.There were stastistical difference between papillary thyroid cancer and normal tissue（P0.001）.The mutation of BRAFV600E was related to lymph node metastasis and TNM stages（P0.05）.Conclusion The mutation of BRAFV600E is a mechanism of papillary thyroid cancer and it is involved in carcinogenesis.BRAFV600E may be an important prognostic indicator of papillary thyroid cancer.
出处
《实用癌症杂志》
2013年第3期246-248,共3页
The Practical Journal of Cancer
关键词
甲状腺肿瘤
BRAF
基因
Thyroid neoplasms
v-raf murine sarcoma viral oncogene homolog B1（BRAF）
Gene
